Literature DB >> 16969365

Genetic variation at the CYP2C locus and its association with torsemide biotransformation.

S V Vormfelde1, M Schirmer, M R Toliat, I Meineke, J Kirchheiner, P Nürnberg, J Brockmöller.   

Abstract

In 97 unselected volunteers and two additional homozygous carriers of CYP2C9(*)3, we investigated the oral clearance of torsemide in relation to 37 polymorphisms at the CYP2C gene locus. Torsemide total oral clearance was linearly associated with the number of CYP2C9(*)3 alleles (geometric mean: 59, 40 and 20 ml/min in carriers of no, one and two alleles) and so were the methyl- and ring-hydroxylation but not the carboxylation clearance. Haplotypes including the CYP2C9(*)3 allele were similarly associated with the clearances but no other variant and no haplotype not including the CYP2C9(*)3 variant. The extended haplotype length (EHL) of the CYP2C9 haplotypes was positively associated with higher activity of the gene product. Torsemide total oral clearance was predictable with r(2)=82.1% using plasma concentrations at 0.5, 1, 2 and 24 h. In conclusion, torsemide's biotransformation strongly depended on the CYP2C9(*)3 variant but no other. Higher clearance CYP2C9 haplotypes appear to be evolutionarily selected.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16969365     DOI: 10.1038/sj.tpj.6500410

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  7 in total

1.  Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Authors:  Makiko Kusama; Kazuya Maeda; Koji Chiba; Akinori Aoyama; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-12-12       Impact factor: 4.200

2.  Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms.

Authors:  Seung-Hyun Jeong; Ji-Hun Jang; Hea-Young Cho; Yong-Bok Lee
Journal:  Pharmaceutics       Date:  2022-04-01       Impact factor: 6.525

3.  Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.

Authors:  Dierk Werner; Ulrike Werner; Annett Meybaum; Boris Schmidt; Sumaira Umbreen; Anton Grosch; Heiko G Lestin; Bernhard Graf; Oliver Zolk; Martin F Fromm
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials.

Authors:  S de Denus; J L Rouleau; D L Mann; G S Huggins; T P Cappola; S H Shah; J Keleti; Y F Zada; S Provost; A Bardhadi; M S Phillips; V Normand; I Mongrain; M-P Dubé
Journal:  Pharmacogenomics J       Date:  2016-03-01       Impact factor: 3.550

5.  A Life-Threatening Case of Torsemide-Induced Toxic Epidermal Necrolysis Associated With the Treatment of Anasarca.

Authors:  Sujana Reddy; Bray K Aron; John Stewart
Journal:  Cureus       Date:  2022-03-06

6.  The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.

Authors:  Xiangkun Wang; Tingdong Yu; Xiwen Liao; Chengkun Yang; Chuangye Han; Guangzhi Zhu; Ketuan Huang; Long Yu; Wei Qin; Hao Su; Xiaoguang Liu; Tao Peng
Journal:  Cancer Med       Date:  2018-02-26       Impact factor: 4.452

7.  Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution.

Authors:  Ramatoulie E Janha; Archibald Worwui; Kenneth J Linton; Seif O Shaheen; Fatoumatta Sisay-Joof; Robert T Walton
Journal:  BMC Evol Biol       Date:  2014-04-01       Impact factor: 3.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.